Sandoz joins Accord in targeting US university

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Sandoz joins Accord in targeting US university

Viersen, Germany - May 9. 2020: Close up of mobile phone screen

The claim, filed this week against the University of California’s governing board, follows action by Accord Healthcare in October

Sandoz has become the second pharmaceutical company in the last few months to take action against the governing board of the University of California, according to a case filed with the England and Wales High Court on Tuesday, January 24.

The generics arm of Swiss outfit Novartis has filed pleadings against The Regents of the University of California. Publicly available documents are expected to be released in early February.

Sandoz filed the case in the patents division of the England and Wales High Court, but no further details are available at this stage.

The case follows action taken by Accord Healthcare in October last year in which the pharma company sought to invalidate a European patent and supplementary protection certificate (SPC) owned by the Regents.

That dispute arose after Accord signalled its intention to produce a capsule form of enzalutamide, a treatment for prostate cancer, in 2024 following the expiry of market exclusivity.

In the Accord case, the Regents first claimed that launching a capsule before the expiry date of a patent (EP 1,893,196) and SPC (GB13/079) it owns would amount to infringement.

In a counterclaim, Accord sought an order that the patent, called ‘diarylhydantoin compound’, is invalid and that the SPC is also invalid and should not come into force.

That case is expected to go to trial in the coming months. It is not known at this stage if the Sandoz dispute surrounds the same claims.

Bristows is representing Sandoz, whereas the Regents’ counsel have not been announced yet. In the Accord case, Pinsent Masons is acting for Accord while the Regents is being represented by Kirkland & Ellis.

more from across site and SHARED ros bottom lb

More from across our site

Via LA’s Qi wireless charging patent pool now covers more than 50% of all SEPs in the space
Vida Panganiban-Alindogan at SyCip Salazar Hernandez & Gatmaitan discusses IP valuation and why no IP practice area is more important than the other
The IP team at Morais Leitão discusses high-stakes litigation, strategic partnerships with clients, and bolstering cross-border expertise
Eszter Szakács discusses 5.30 am wake-ups, legal mind games, and eating Nutella in the middle of the night
Counsel explain how AI can create brand protection headaches, but also be used to fight fakes
An AI copyright update in the UK and IP protection efforts by Temu and WeChat were also among the top talking points this week
Mary Till says she has been helping clients navigate policy questions, including staffing concerns at the office
A seminal decision concerning second medical use patents and questions over confidentiality were among the top talking points this fortnight
Managing IP considers some of the key themes from the 2025 Annual Meeting and offers some tips for London 2026
A comparison of the 2024 and 2025 editions of the Managing IP EMEA Awards reveals the firms and companies that have been dominating Europe’s IP market year after year
Gift this article